WSJ -- Roche Holding AG Thursday confirmed its full-year outlook as the Swiss pharmaceutical giant posted a bigger-than-expected 5.8% rise in first-quarter sales, spurred by renewed demand for its flagship cancer drug Avastin and a strong performance in emerging markets.
